Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

U.S. Markets are not yet open, but HALO is being traded in the pre-market session. Pre-Market quote »
7.90
Delayed Data
As of Feb 05
 -0.37 / -4.47%
Today’s Change
7.49
Today|||52-Week Range
25.25
-54.41%
Year-to-Date

Today’s Trading

Previous close8.27
Today’s open8.21
Day’s range7.75 - 8.44
Volume2,040,418
Average volume (3 months)1,432,284
Market cap$1.0B
Dividend yield--
Data as of 02/05/2016

Growth & Valuation

Earnings growth (last year)+24.32%
Earnings growth (this year)+34.74%
Earnings growth (next 5 years)--
Revenue growth (last year)+37.47%
P/E ratioNM
Price/Sales15.72
Price/Book24.02

Competitors

 Today’s
change
Today’s
% change
MCRBSeres Therapeutics I...-1.22-4.64%
AXONAxovant Sciences Ltd-2.16-16.13%
FPRXFive Prime Therapeut...-1.72-5.17%
MNTAMomenta Pharmaceutic...-0.65-5.23%
Data as of 02/05/2016

Financials

Next reporting dateMarch 1, 2016
EPS forecast (this quarter)-$0.08
Annual revenue (last year)$75.3M
Annual profit (last year)-$68.4M
Net profit margin-90.76%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
--, --

Forecasts

Partner Offers